Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients
Authors:
Open Access
- 9 October 2021
- journal article
- review article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 26 (12) , 2194-2204
Abstract
This study aimed to investigate risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients through a meta-analysis. A comprehensive retrieve of Chinese databases China National Knowledge Infrastructure, Wanfang Data, VIP Database and English databases PubMed, ScienceDirect, Embase and Cochrane library was conducted. The studies that meet the requirements for meta-analysis according to inclusion and exclusion criteria were screened and assessed for eligibility. Odds ratio (OR) / Weighted mean difference (WMD) and 95% confidence intervals (95% CIs) or calculable dichotomous and continuous raw data were extracted to perform meta-analysis using random effect model or fixed effect model on the basis of heterogeneity between studies through Review Manager 5.4 software. A total of 14 cross-sectional studies and 3367 cancer patients were included. Meta-analysis results showed that platinum exposure history (OR value 3.13, 95% CI 2.19–4.48, heterogeneity P = 0.26), allergy history (OR value 1.76, 95% CI 1.09–2.85, heterogeneity P = 0.61), platinum free interval (OR value 3.75, 95% CI 2.00–7.06, heterogeneity P = 0.83), dexamethasone premedication dose (OR value 0.28, 95% CI 0.13–0.58, heterogeneity P = 0.21) were significantly correlated to oxaliplatin hypersensitivity reactions. Gender, age, metastasis, combination with bevacizumab, XELOX regimen and cancer types were detected to have no statistically significant effect on oxaliplatin hypersensitivity reactions. Platinum exposure history, allergy history and long platinum-free interval are risk factors of oxaliplatin hypersensitivity reactions. High dexamethasone premedication dose is a protective factor of oxaliplatin hypersensitivity reactions.Keywords
Funding Information
- Key Innovative Team of Shanghai Top-Level University Capacity Building in Clinical Pharmacy and Regulatory Science at Shanghai Medical College, Fudan University (Shanghai Municipal Education Commission, HJW-R-2019-66-19)
- Shanghai “Rising Stars of Medical Talent” Youth Development Program Youth Medical Talents Clinical Pharmacist Program (SHWRS(2020)_087)
- “Clinical Research Plan of SHDC” (SHDC2020CR3085B)
This publication has 40 references indexed in Scilit:
- Hypersensitivity to oxaliplatin: clinical features and risk factorsBMC Pharmacology and Toxicology, 2014
- World Allergy Organization Anaphylaxis Guidelines: 2013 Update of the Evidence BaseInternational Archives of Allergy and Immunology, 2013
- High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatinInternational Journal of Clinical Oncology, 2011
- Oxaliplatin-Free Interval as a Risk Factor for Hypersensitivity Reaction among Colorectal Cancer Patients Treated with FOLFOXOncology, 2010
- Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic ReviewMetal-Based Drugs, 2010
- Oxaliplatin-induced allergic reaction in patients with colorectal cancer in JapanInternational Journal of Clinical Oncology, 2009
- Hypersensitivity to Oxaliplatin: An Investigation of Incidence and Risk Factors, and Literature ReviewOncology, 2009
- Hypersensitivity reactions associated with oxaliplatinExpert Opinion on Drug Safety, 2006
- Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institutionAnti-Cancer Drugs, 2003
- Measuring inconsistency in meta-analysesBMJ, 2003